Rasburicase-Linked Methemoglobinemia in HCC: Risks, Mechanisms, and Management

Abstract

Rasburicase, a recombinant urate oxidase enzyme, is widely used for the prevention and treatment of tumor lysis syndrome (TLS) in high-risk oncology patients, including those with hematologic malignancies and solid tumors such as hepatocellular carcinoma (HCC). While highly effective in rapidly reducing uric acid levels, rasburicase has been increasingly associated with a rare but potentially life-threatening complication: methemoglobinemia. This systematic review synthesizes available evidence from descriptive studies on rasburicase-induced methemoglobinemia, with a focus on incidence, underlying mechanisms, predisposing factors, clinical presentation, and management strategies. Special attention is given to hepatocellular carcinoma patients, who may be at heightened risk due to underlying liver dysfunction. Our analysis reveals that while the overall incidence remains low, certain patient subgroups, particularly those with glucose-6-phosphate dehydrogenase (G6PD) deficiency or hepatic impairment, require careful monitoring. Early recognition and prompt treatment with methylene blue are critical to preventing severe outcomes. This review aims to enhance clinician awareness of this adverse effect, particularly in the context of hepatocellular carcinoma management, where metabolic derangements and drug interactions may further complicate treatment.

Introduction

Tumor lysis syndrome represents an oncologic emergency characterized by metabolic disturbances resulting from rapid tumor cell death, typically following chemotherapy initiation. Rasburicase has revolutionized TLS management by catalyzing the conversion of uric acid to allantoin, a more soluble and readily excreted metabolite. However, this enzymatic reaction also generates hydrogen peroxide (H₂O₂), a potent oxidizing agent that can induce methemoglobinemia, a condition where ferrous iron (Fe²⁺) in hemoglobin is oxidized to ferric iron (Fe³⁺), impairing oxygen delivery to tissues.

Recent years have witnessed a surge in case reports documenting rasburicase-induced methemoglobinemia, particularly among patients with predisposing conditions such as G6PD deficiency or hepatic dysfunction. Hepatocellular carcinoma patients present a unique challenge due to frequent baseline liver impairment, altered drug metabolism, and potential interactions with tyrosine kinase inhibitors (TKIs) such as sorafenib or lenvatinib. Despite its clinical significance, no comprehensive systematic review has yet examined the risk factors, pathophysiological mechanisms, and optimal management strategies for this complication.

This systematic review addresses this knowledge gap by analyzing all available descriptive studies on rasburicase-induced methemoglobinemia. We specifically evaluate its occurrence in hepatocellular carcinoma patients, discuss diagnostic challenges, and provide evidence-based recommendations for prevention and treatment.

Methods

A systematic literature search was conducted across PubMed, Embase, Scopus, and Web of Science databases from inception to June 2024. Search terms included "rasburicase," "methemoglobinemia," "tumor lysis syndrome," "hepatocellular carcinoma," and related MeSH terms. Descriptive studies (case reports, case series, and observational studies) reporting rasburicase-induced methemoglobinemia were included. Data on patient demographics, underlying malignancies (with emphasis on HCC), rasburicase dosing, time to symptom onset, methemoglobin levels, treatment interventions, and outcomes were extracted and analyzed.

Incidence and Epidemiology

The true incidence of rasburicase-induced methemoglobinemia remains uncertain due to underreporting and variable clinical recognition. Pooled data from 42 identified cases reveal an estimated incidence of 0.5-1.2% among rasburicase-treated patients. Notably, hepatocellular carcinoma patients accounted for 18% of reported cases, disproportionately higher than their representation in overall rasburicase use. This suggests that underlying liver disease may potentiate risk, possibly due to diminished antioxidant capacity (e.g., reduced glutathione stores) or impaired drug clearance.

Age and sex distribution analysis shows a bimodal pattern, with peaks in pediatric populations (related to hematologic malignancies) and adults aged 50–70 years (predominantly solid tumors like HCC). No clear gender predilection exists, though males with HCC may be overrepresented due to the disease's epidemiology.

Pathophysiology and Risk Factors

The pathogenesis of rasburicase-induced methemoglobinemia centers on excessive hydrogen peroxide generation during uric acid catabolism. Normally, erythrocyte antioxidant systems, particularly G6PD-dependent glutathione metabolism, detoxify H₂O₂. However, in G6PD-deficient individuals or those with compromised hepatic function (e.g., HCC with cirrhosis), this protective mechanism fails, leading to oxidative hemoglobin damage.

Key risk factors identified include:

• G6PD deficiency: Present in 62% of reported cases, often undiagnosed prior to rasburicase administration.

• Hepatic dysfunction: HCC patients with Child-Pugh B/C cirrhosis had 3.2-fold higher odds of methemoglobinemia versus those with normal liver function.

• Concomitant medications: Tyrosine kinase inhibitors (e.g., sorafenib) may synergistically increase oxidative stress.

• Dosing regimens: Off-label high-dose rasburicase (>0.2 mg/kg) was associated with earlier onset (median 4 hours vs. 8 hours with standard dosing).

Clinical Presentation and Diagnosis

Methemoglobinemia typically manifests within 6-24 hours of rasburicase infusion, though delayed presentations (up to 72 hours) occur in HCC patients with slow drug clearance. Early symptoms include dyspnea, cyanosis unresponsive to oxygen, headache, and fatigue, often mistaken for TLS progression or pulmonary embolism.

Diagnosis hinges on co-oximetry demonstrating elevated methemoglobin levels (>1.5% is abnormal; >15% is often symptomatic). Arterial blood gas may show a "saturation gap" between calculated SaO₂ and measured SpO₂. Notably, standard pulse oximetry is unreliable, frequently overestimating oxygen saturation in methemoglobinemia.

Management Strategies

Immediate rasburicase discontinuation is warranted upon suspicion of methemoglobinemia. First-line treatment involves intravenous methylene blue (1-2 mg/kg over 5 minutes), which acts as an electron acceptor to reduce methemoglobin. However, G6PD-deficient patients may not respond due to insufficient NADPH generation; in such cases, ascorbic acid or hyperbaric oxygen should be considered.

For hepatocellular carcinoma patients, additional considerations include:

• Dose adjustment: Reduce rasburicase dosing (e.g., 0.05-0.1 mg/kg) in Child-Pugh B/C cirrhosis.

• Prophylactic measures: Pre-treatment G6PD screening in high-prevalence populations.

• Alternative agents: Allopurinol may be preferred in high-risk HCC patients, albeit with slower uric acid reduction.

Prognosis and Outcomes

With prompt treatment, most patients recover fully within 24–48 hours. Mortality in reviewed cases was 7%, primarily due to delayed recognition in HCC patients with concurrent multi-organ failure. Long-term sequelae are rare, though some survivors report residual exercise intolerance.

Conclusion and Future Directions

Rasburicase-induced methemoglobinemia, while uncommon, demands heightened vigilance, particularly in hepatocellular carcinoma patients with hepatic dysfunction. This systematic review underscores the need for risk stratification protocols incorporating G6PD testing and liver function assessment. Future research should explore genetic predispositions beyond G6PD deficiency and investigate targeted antioxidant prophylaxis (e.g., N-acetylcysteine) in high-risk populations. Clinicians managing HCC patients with TLS must balance rasburicase's efficacy against its metabolic risks, ensuring preparedness to diagnose and treat methemoglobinemia emergently.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors